Thurston, Springer, Miller, Herd & Titak, Inc. Crispr Therapeutics Ag Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $730 Million
- Q2 2025
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 1,465 shares of CRSP stock, worth $74,993. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,465
Previous 1,345
8.92%
Holding current value
$74,993
Previous $45,000
57.78%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding CRSP
# of Institutions
481Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$520 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$311 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$194 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$142 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$130 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.99B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....